Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Schäfer

Showing results (1-10 of 280) with videos related to

Pageof 28
Sort By:
Journal of Clinical Medicine|August 12, 2022
Interventional Cardiology: Current Challenges in Acute Myocardial InfarctionAndreas Schäfer
International Journal of Cardiology|January 29, 2022
Clopidogrel or ticagrelor in elderly patients with acute coronary syndromes - Nihil nocere!Andreas Schäfer
Cardiovascular Drugs and Therapy|September 26, 2012
Breaking resistance: is there still a reason for clopidogrel in acute STEMI? : editorial to: "prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction" by D. Alexopoulos et alAndreas Schäfer
Deutsche Medizinische Wochenschrift (1946)|April 15, 2024
[Antithrombotic therapy in acute coronary syndrome]Andreas Schäfer
Current Vascular Pharmacology|August 24, 2004
Endothelial dysfunction in heart failure: mechanisms and therapeutic approachesJohann Bauersachs, Andreas Schäfer
Cardiovascular Research|February 22, 2005
Tetrahydrobiopterin and eNOS dimer/monomer ratio--a clue to eNOS uncoupling in diabetes?Johann Bauersachs, Andreas Schäfer
Organic Letters|January 28, 2017
Synthesis of the Cyclohepta[e]hydrindane Core of the Marine Homoverrucosane Diterpenoid Gagunin EAndreas Schäfer, Martin Hiersemann
Pharmacology & Therapeutics|November 6, 2021
P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention - Understanding the debate on Prasugrel or TicagrelorAndreas Schäfer, Johann Bauersachs
Thrombosis and Haemostasis|June 29, 2012
Fractalkine--a local inflammatory marker aggravating platelet activation at the vulnerable plaqueUlrike Flierl, Andreas Schäfer
Current Vascular Pharmacology|January 29, 2008
Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosisAndreas Schäfer, Johann Bauersachs
Pageof 28

Showing results (1-10 of 280) with videos related to

Sort By:
Pageof 28
Journal of Clinical Medicine|August 12, 2022
Interventional Cardiology: Current Challenges in Acute Myocardial InfarctionAndreas Schäfer
International Journal of Cardiology|January 29, 2022
Clopidogrel or ticagrelor in elderly patients with acute coronary syndromes - Nihil nocere!Andreas Schäfer
Cardiovascular Drugs and Therapy|September 26, 2012
Breaking resistance: is there still a reason for clopidogrel in acute STEMI? : editorial to: "prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction" by D. Alexopoulos et alAndreas Schäfer
Deutsche Medizinische Wochenschrift (1946)|April 15, 2024
[Antithrombotic therapy in acute coronary syndrome]Andreas Schäfer
Current Vascular Pharmacology|August 24, 2004
Endothelial dysfunction in heart failure: mechanisms and therapeutic approachesJohann Bauersachs, Andreas Schäfer
Cardiovascular Research|February 22, 2005
Tetrahydrobiopterin and eNOS dimer/monomer ratio--a clue to eNOS uncoupling in diabetes?Johann Bauersachs, Andreas Schäfer
Organic Letters|January 28, 2017
Synthesis of the Cyclohepta[e]hydrindane Core of the Marine Homoverrucosane Diterpenoid Gagunin EAndreas Schäfer, Martin Hiersemann
Pharmacology & Therapeutics|November 6, 2021
P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention - Understanding the debate on Prasugrel or TicagrelorAndreas Schäfer, Johann Bauersachs
Thrombosis and Haemostasis|June 29, 2012
Fractalkine--a local inflammatory marker aggravating platelet activation at the vulnerable plaqueUlrike Flierl, Andreas Schäfer
Current Vascular Pharmacology|January 29, 2008
Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosisAndreas Schäfer, Johann Bauersachs
Pageof 28